Novo Nordisk teams with OpenAI

Novo Nordisk said Tuesday it will roll out OpenAI tools across drug research, factories, supply chains and sales operations. (reuters.com) The Danish drugmaker said the partnership starts with pilot programs in research and development, manufacturing and commercial teams, with broader integration targeted by the end of 2026. (cnbc.com) Novo said the system will be used to analyze large datasets, identify possible drug targets, support manufacturing and distribution work, and train employees to use artificial intelligence tools under human oversight and data-governance rules. (novonordisk.com) Drug discovery is the process of sorting through huge amounts of biology and chemistry data to find molecules worth testing, and companies are using artificial intelligence as a faster pattern-finding tool. Novo said it wants that process to move faster as it develops treatments for chronic diseases. (cnbc.com) The timing is tied to a tougher stretch for Novo in obesity drugs. Reuters reported the company has fallen behind Eli Lilly in the weight-loss market, even as Novo remains the maker of Ozempic and Wegovy. (reuters.com) Novo has already been building out its artificial intelligence stack. Bloomberg reported the OpenAI deal adds to an earlier research-focused partnership with Nvidia that Novo announced in 2025. (bloomberg.com) The company did not disclose financial terms of the OpenAI agreement. Reuters and Bloomberg both reported that detail on April 14. (reuters.com; bloomberg.com) OpenAI has been pushing deeper into enterprise deals, while drugmakers have been testing whether these systems can shorten the early stages of research without handing final decisions to software. Novo said its rollout will be global, but the company kept the message simple: use the tools to help employees move faster. (novonordisk.com; wsj.com)